Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Study sponsor: Replimune, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-12-01Estimated
Enrollment · participants60Estimated
Source updated2026-04-02Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.